CR20170359A - Oligómetros antisentido de tau y usos de estos - Google Patents

Oligómetros antisentido de tau y usos de estos

Info

Publication number
CR20170359A
CR20170359A CR20170359A CR20170359A CR20170359A CR 20170359 A CR20170359 A CR 20170359A CR 20170359 A CR20170359 A CR 20170359A CR 20170359 A CR20170359 A CR 20170359A CR 20170359 A CR20170359 A CR 20170359A
Authority
CR
Costa Rica
Prior art keywords
tau
oluometers
antisentido
expression
tau protein
Prior art date
Application number
CR20170359A
Other languages
English (en)
Inventor
Marianne Lerbech Jensen
Anja Mølhart Høg
Niels Fisker Nielsen
Angela M Cacace
Peter Hagedorn
Jeffrey M Brown
Dong Li
Stephen E Mercer
Richard E Olson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20170359A publication Critical patent/CR20170359A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a compuestos de oligómeros (oligómeros), que se dirigen a ARNm Tau en una célula, lo que conduce a una expresión menor de la proteína Tau. La reducción de la expresión de la proteína Tau es beneficiosa para el tratamiento de ciertos trastornos médicos, por ejemplo, un trastorno neurológico.
CR20170359A 2015-02-04 2016-02-04 Oligómetros antisentido de tau y usos de estos CR20170359A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562112058P 2015-02-04 2015-02-04
US201562156684P 2015-05-04 2015-05-04
US201562237922P 2015-10-06 2015-10-06
US201562238941P 2015-10-08 2015-10-08
US201662279614P 2016-01-15 2016-01-15
US201662279612P 2016-01-15 2016-01-15
US201662279610P 2016-01-15 2016-01-15
PCT/US2016/016646 WO2016126995A1 (en) 2015-02-04 2016-02-04 Tau antisense oligomers and uses thereof

Publications (1)

Publication Number Publication Date
CR20170359A true CR20170359A (es) 2017-11-24

Family

ID=55443327

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170359A CR20170359A (es) 2015-02-04 2016-02-04 Oligómetros antisentido de tau y usos de estos

Country Status (24)

Country Link
US (3) US10799523B2 (es)
EP (2) EP3653712B1 (es)
JP (1) JP2018505676A (es)
KR (1) KR20180016970A (es)
CN (1) CN107922946A (es)
AU (1) AU2016215155A1 (es)
BR (1) BR112017016663A2 (es)
CA (1) CA2975525A1 (es)
CL (1) CL2017001956A1 (es)
CO (1) CO2017009008A2 (es)
CR (1) CR20170359A (es)
DK (1) DK3253875T3 (es)
HK (1) HK1248276A1 (es)
IL (1) IL253730A0 (es)
MA (1) MA41586A (es)
MX (1) MX2017010066A (es)
PE (1) PE20171766A1 (es)
PH (1) PH12017550069A1 (es)
RU (1) RU2017127609A (es)
SG (1) SG11201706293XA (es)
TW (1) TW201641691A (es)
UY (1) UY36550A (es)
WO (1) WO2016126995A1 (es)
ZA (1) ZA201705119B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
AU2012284265B2 (en) 2011-07-19 2017-08-17 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
AU2013203395A1 (en) 2012-03-30 2013-10-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
EP3254104B1 (en) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
PH12018501207B1 (en) * 2015-12-21 2024-02-23 Novartis Ag Compositions and methods for decreasing tau expression
ES2963428T3 (es) 2016-09-29 2024-03-27 Biogen Ma Inc Compuestos y métodos para reducir la expresión de Tau
CN110214184B (zh) * 2016-12-01 2024-07-02 桑格摩生物治疗股份有限公司 τ蛋白调节剂以及用于其递送的方法和组合物
PT3717646T (pt) * 2017-12-01 2025-07-28 Texas A & M Univ Sys Tratamento antisense da síndrome de angelman
EA202091693A1 (ru) 2018-01-12 2021-04-14 Бристол-Маерс Сквибб Компани Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
BR112020013994A2 (pt) 2018-01-12 2020-12-08 Bristol-Myers Squibb Company Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos
CA3088071A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Oligonucleotides for modulating tmem106b expression
AU2019218987B2 (en) 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
KR20200131263A (ko) 2018-03-13 2020-11-23 얀센 파마슈티카 엔.브이. 변형 올리고뉴클레오티드 및 타우병증에서의 사용 방법
US11613554B2 (en) 2018-04-13 2023-03-28 Bristol-Myers Squibb Company Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds
WO2019233922A1 (en) 2018-06-05 2019-12-12 F. Hoffmann-La Roche Ag Oligonucleotides for modulating atxn2 expression
SG11202012759XA (en) * 2018-07-03 2021-01-28 Hoffmann La Roche Oligonucleotides for modulating tau expression
KR20210070344A (ko) 2018-10-02 2021-06-14 상가모 테라퓨틱스, 인코포레이티드 타우 단백질의 조정을 위한 방법 및 조성물
KR20210149107A (ko) * 2019-04-03 2021-12-08 브리스톨-마이어스 스큅 컴퍼니 Angptl2 안티센스 올리고뉴클레오티드 및 그의 용도
US11286485B2 (en) 2019-04-04 2022-03-29 Hoffmann-La Roche Inc. Oligonucleotides for modulating ATXN2 expression
JP7499267B2 (ja) 2019-04-04 2024-06-13 エフ． ホフマン－ラ ロシュ アーゲー Ａｔｘｎ２発現を調節するためのオリゴヌクレオチド
EP3980539A1 (en) 2019-06-06 2022-04-13 F. Hoffmann-La Roche AG Antisense oligonucleotides targeting atxn3
CN114401713A (zh) 2019-09-17 2022-04-26 Zyne制药公司 在发育性和癫痫性脑病中的行为损伤的治疗
IL294618A (en) 2020-01-16 2022-09-01 Bristol Myers Squibb Co Reagents and their use for the modular synthesis of c-p bonds
AU2021246024A1 (en) * 2020-03-30 2022-10-27 Alnylam Pharmaceuticals, Inc. Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof
US20230212572A1 (en) 2020-06-09 2023-07-06 Roche Innovation Center Copenhagen A/S Guanosine Analogues for Use in Therapeutics Polynucleotides
TW202237842A (zh) 2020-12-03 2022-10-01 瑞士商赫孚孟拉羅股份公司 靶向ａｔｘｎ３之反義寡核苷酸
WO2022117747A2 (en) 2020-12-03 2022-06-09 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting atxn3
US20220195437A1 (en) * 2020-12-11 2022-06-23 Eisai R&D Management Co., Ltd. Tau-targeting oligonucleotide gapmers
CA3211396A1 (en) * 2021-02-17 2022-08-25 Q-State Biosciences, Inc. Ube3a antisense therapeutics
WO2023278436A1 (en) * 2021-06-29 2023-01-05 Shape Therapeutics Inc. Engineered guide rnas and polynucleotides
KR20240067943A (ko) 2021-09-24 2024-05-17 알닐람 파마슈티칼스 인코포레이티드 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
US20250340872A1 (en) * 2021-10-07 2025-11-06 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing tau expression
WO2023217437A1 (en) * 2022-05-13 2023-11-16 Julius-Maximilians-Universität Würzburg Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease
KR20250119484A (ko) * 2024-01-30 2025-08-07 소바젠 주식회사 Mtor 활성 또는 발현을 조절하기 위한 화합물 및 이의 용도

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5157021A (en) 1985-03-15 1992-10-20 Novo Nordisk A/S Insulin derivatives and pharmaceutical preparations containing these derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5453491A (en) 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
WO1992018628A1 (en) 1991-04-19 1992-10-29 Schering Corporation Subunit of the human interleukin-3 receptor
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5227158A (en) 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DE69628652T3 (de) 1995-09-08 2012-05-03 Genentech, Inc. Vegf-verwandtes protein
IL127558A0 (en) 1996-07-03 1999-10-28 Genentech Inc Hepatocyte growth factor receptor agonists and uses thereof
US6159462A (en) 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
GB9812127D0 (en) 1998-06-06 1998-08-05 Univ Glasgow Detection of neural activity
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
DE69939553D1 (de) 1998-12-30 2008-10-23 Beth Israel Hospital Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
CN100572392C (zh) * 2002-07-12 2009-12-23 阿克松神经科学研究和发展股份有限公司 截短tau蛋白
US9045518B2 (en) * 2002-11-18 2015-06-02 Santaris Pharma A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
US20040248840A1 (en) 2003-02-10 2004-12-09 Santaris Pharma A/S Oligomeric compounds for the modulation of ras expression
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
EP2397563A3 (en) 2004-09-17 2012-07-18 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
EP2023940B1 (en) 2006-05-05 2011-06-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
WO2008049085A1 (en) 2006-10-18 2008-04-24 Isis Pharmaceuticals, Inc. Antisense compounds
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2009090182A1 (en) 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US8846639B2 (en) 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
DK2285819T3 (da) 2008-04-04 2013-12-02 Isis Pharmaceuticals Inc Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
CN101812127B (zh) * 2009-02-19 2013-03-06 中国科学技术大学 微管结合蛋白及其编码基因与应用
US20100275274A1 (en) * 2009-04-28 2010-10-28 National Yang-Ming University Mouse model for depression, schizophrenia and alzheimer's disease
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2490699A1 (en) 2009-10-20 2012-08-29 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
WO2011085102A1 (en) 2010-01-11 2011-07-14 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011115818A1 (en) 2010-03-17 2011-09-22 Isis Pharmaceuticals, Inc. 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2561340B1 (en) 2010-04-21 2019-01-23 Vanderlande APC Inc. Method and system for use in performing security screening
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US8778884B2 (en) 2011-05-26 2014-07-15 Fondazione Salvatore Maugeri Clinica del Lavora e Della Riabilitazione Glioprotectant peptide for use in the treatment of amyotrophic lateral sclerosis (ALS) and methods related thereto
US9243291B1 (en) 2011-12-01 2016-01-26 Isis Pharmaceuticals, Inc. Methods of predicting toxicity
AU2013203395A1 (en) * 2012-03-30 2013-10-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013159108A2 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US20160138014A1 (en) 2012-10-12 2016-05-19 Isis Pharmaceuticals, Inc. Antisense compounds and uses thereof
CN104936977B (zh) * 2012-10-24 2019-10-08 开普敦大学 微管修饰化合物
US9014359B1 (en) 2013-01-11 2015-04-21 Time Warner Cable Enterprises Llc Generation of phone number lists and call filtering
ES2807379T3 (es) 2013-03-14 2021-02-22 Ionis Pharmaceuticals Inc Composiciones y métodos para regular la expresión de Tau
JP2016523980A (ja) 2013-07-11 2016-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク タウ発現を抑制するマイクロｒｎａ
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
WO2016019063A1 (en) 2014-07-29 2016-02-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
JP6350987B2 (ja) 2014-08-04 2018-07-04 本田技研工業株式会社 ＧＨファミリー３に属する耐熱性β―キシロシダーゼ

Also Published As

Publication number Publication date
CN107922946A (zh) 2018-04-17
EP3253875A1 (en) 2017-12-13
HK1248276A1 (zh) 2018-10-12
TW201641691A (zh) 2016-12-01
US20220143064A1 (en) 2022-05-12
RU2017127609A (ru) 2019-03-04
BR112017016663A2 (pt) 2018-04-10
EP3653712B1 (en) 2022-11-30
US10799523B2 (en) 2020-10-13
SG11201706293XA (en) 2017-09-28
IL253730A0 (en) 2017-09-28
AU2016215155A1 (en) 2017-08-17
JP2018505676A (ja) 2018-03-01
ZA201705119B (en) 2020-01-29
US20160237427A1 (en) 2016-08-18
US20180161356A1 (en) 2018-06-14
US11077132B2 (en) 2021-08-03
MX2017010066A (es) 2017-11-01
WO2016126995A1 (en) 2016-08-11
KR20180016970A (ko) 2018-02-20
MA41586A (fr) 2017-12-13
EP3253875B1 (en) 2020-01-08
CO2017009008A2 (es) 2017-11-21
PH12017550069A1 (en) 2018-02-05
DK3253875T3 (da) 2020-04-14
UY36550A (es) 2016-08-31
CL2017001956A1 (es) 2018-06-01
CA2975525A1 (en) 2016-08-11
PE20171766A1 (es) 2017-12-21
EP3653712A1 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
CR20170359A (es) Oligómetros antisentido de tau y usos de estos
CL2018000899A1 (es) Compuestos y métodos para modular expresión de angiotensinógeno.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
CO2018006590A2 (es) Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2017001046A1 (es) Inhibidoes del bromodominio
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
MX377141B (es) Composiciones y metodos para modular la expresion de pkk.
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
MX2018005165A (es) Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.
CL2017001960A1 (es) Métodos de tratamiento de enfermedades inflamatorias
CO2020009715A2 (es) Oligonucleótidos antisentido que actúan sobre alfa-sinucleína, y usos de estos
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
MX2017009246A (es) Farmaco de combinacion.
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
BR112018003928A2 (pt) métodos para o tratamento de doenças
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
CL2018002128A1 (es) Composiciones y métodos para el tratamiento de heridas crónicas
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
CO2020008425A2 (es) Oligonucleótidos antisentido que actúan sobre alfa-sinucleína, y usos de estos
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.